Oramed (ORMP) Fundamental Analysis: Revenue, Earnings & Valuation

8.49 / 10

Outperform

Fundamentals score 8.5/10, rated Outperform. Strong interest coverage (35.1) and PB‑ROE advantage, high inventory turnover (104) and robust revenue growth (>130% YoY). Weaknesses include high current‑liabilities ratio (61%) and negative revenue‑to‑market value. Overall, fundamentals are highly favorable.

Analysis Checks(7/10)

Revenue-MV

Value-0.28

Score1/3

Weight19.73%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.55%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-4.53%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value61.33

Score1/3

Weight-6.34%

1M Return-1.69%

PB-ROE

Value-0.58

Score3/3

Weight50.04%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.11

Score2/3

Weight-1.40%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.60%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.22%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score1/3

Weight-23.41%

1M Return-7.95%

Asset-MV

Value-0.49

Score3/3

Weight69.75%

1M Return11.61%

Is ORMP undervalued or overvalued?

ORMP scores 8.49/10 on fundamentals and holds a Discounted valuation at present. Backed by its 37.12% ROE, 3200.80% net margin, 2.16 P/E ratio, 0.69 P/B ratio, and 418.75% earnings growth, these metrics solidify its Outperform investment rating.